If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.30    -0.05 (-0.79%)
Bid:
6.20
Ask:
6.40
Spread: 0.20 (3.226%)
Market Cap: £6.51m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half Yearly Results

18 Jul 2014 07:00

RNS Number : 6690M
Ducat Ventures PLC
18 July 2014
 



Ducat Ventures Plc ("Company")

 

Half Yearly Report

 

The Board of Ducat presents the unaudited historical financial information of the Company for the 6 months to 31 May 2014. 

 

Consolidated Statement of Comprehensive Income

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

 to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

Continuing operations

 

 

£

£

 

 

 

 

 

Revenue

 

 

-

-

Cost of Sales

 

 

-

-

 

 

 

───────

───────

 

 

 

 

 

Gross Loss

 

 

-

-

 

 

 

 

 

Administrative expenses

 

 

(57,643)

(166,453)

 

 

 

───────

───────

Operating Loss

 

 

(57,643)

(166,453)

 

 

 

 

 

Non Operating Items

 

 

 

 

Impairment of investments

 

 

-

(500,000)

Impairment of intercompany loans

 

 

-

(1,384,068)

Surplus arising on settlements with trade creditors

 

 

 

-

 

-

 

 

 

───────

───────

 

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Finance Costs

 

 

-

-

 

 

 

───────

───────

Loss Before Tax

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Taxation

 

 

-

-

 

 

 

───────

───────

Total comprehensive income for the period

 

 

 

(57,643)

 

(2,050,521)

 

 

 

═══════

═══════

 

 

 

 

 

Loss per share

 

 

0.006p

2.29p

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

Consolidated Balance Sheet

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

ASSETS

 

 

£

£

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

Trade and other receivables

 

 

10,034

49,077

Cash and cash equivalents

 

 

105,221

4,945

 

 

 

───────

───────

 

 

 

115,255

54,022

 

 

 

───────

───────

 

 

 

 

 

Total Assets

 

 

115,255

54,022

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

Shareholders' Equity

 

 

 

 

Called up share capital

 

 

5,742,586

5,636,083

Share premium

 

 

1,355,502

1,086,875

Share based payment reserve

 

 

27,200

27,200

Retained earnings

 

 

(7,013,950)

(6,830,754)

 

 

 

───────

───────

Total Equity

 

 

111,338

(80,596)

 

 

 

───────

───────

 

 

 

 

 

LIABILITIES

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

 

3,917

134,618

 

 

 

───────

───────

 

 

 

3,917

134,618

 

 

 

───────

───────

Total Equity and Liabilities

 

 

115,255

54,022

 

 

 

══════

═══════

 

 

 

Consolidated statement of changes in equity

For the six months ended May 2014

 

 

 

 

Called up

Share

Capital

 

 

Share

Premium

Share-

Based

Payment

Reserve

 

 

Retained

Earnings

 

 

Total

Equity

 

£

£

£

£

£

 

 

 

 

 

 

Balance at 1 August 2012

5,574,070

838,822

27,200

(4,780,233)

1,659,859

 

 

 

 

 

 

Loss for period

-

-

-

(2,050,521)

(2,050,521)

 

 

 

 

 

 

Issue of shares

62,013

248,053

-

-

310,066

 

───────

──────

──────

───────

───────

Balance at 31 May 2013

5,636,083

1,086,875

27,200

(6,830,754)

(80,596)

 

 

 

 

 

 

Loss for the period

-

-

-

(125,553)

(125,553)

 

 

 

 

 

 

Issue of shares

86,165

215,936

-

-

302,101

 

───────

──────

──────

───────

───────

Balance at 30 November 2013

5,722,248

1,302,811

27,200

(6,956,307)

95,952

 

 

 

 

 

 

Loss for the period

-

-

-

(57,643)

(57,643)

 

 

 

 

 

 

Issue of ordinary shares at £0.0004 per shares less cost

 

20,338

 

52,691

-

 

 

-

 

73,029

 

───────

──────

──────

───────

───────

Balance at 31 May 2014

5,742,586

1,355,502

27,200

(7,013,950)

113,338

 

══════

══════

══════

══════

═══════

 

 

Consolidated Statement of Cash Flows

As at 31 May 2014

 

 

 

 

 

Six months

 to 31 May

2014

Six months 

to 31 May

2013

 

 

(Unaudited)

(Unaudited)

 

 

£

£

 

 

 

 

Cash flows from operating activities

 

 

 

Loss before tax

 

(57,643)

(166,453)

(Increase)/decrease in trade and other

 receivables

 

 

291,233

 

(81,262)

Increase)/decrease in trade and other

payables

 

 

(201,548)

 

(57,416)

 

 

───────

───────

Net cash from operating activities

 

32,042

(305,131)

 

 

───────

───────

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

Issue of equity net of costs

 

73,029

310,067

Finance interest paid

 

-

-

 

 

───────

───────

Net cash from financing activities

 

73,029

310,067

 

 

───────

───────

 

 

 

 

Increase/(decrease) in cash and cash

equivalents

 

 

105,071

 

4,936

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

150

 

9

 

 

───────

───────

Cash and cash equivalents at the end of period

 

 

105,221

 

4,945

 

 

══════

═══════

 

 

 

 

 

Enquiries:

 

For further information, please contact:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Avi Robinson

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Duncan Vasey

020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGMNVNFGDZM
Date   Source Headline
6th Apr 20207:00 amRNSSlimBiome® contract manufacturing agreement
2nd Apr 20207:00 amRNSSlimBiome® contract manufacturing agreement
31st Mar 20207:00 amRNSExclusive licence agreement for OptiBiome®
24th Mar 20207:00 amRNSExtension of territories for GoFigure®
23rd Mar 20207:00 amRNSChange of accounting year end
19th Mar 20204:42 pmRNSSecond Price Monitoring Extn
19th Mar 20204:38 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 202011:05 amRNSSecond Price Monitoring Extn
19th Mar 202011:00 amRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDistribution Agreement for SlimBiome® Medical
16th Mar 202011:56 amRNSDirector’s Dealing
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:39 pmRNSPrice Monitoring Extension
12th Mar 20202:05 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
12th Mar 20207:00 amRNSNew partner for LPLDL® in Bulgaria
11th Mar 20207:00 amRNSExtension of LPLDL® supply agreement with SACCO
25th Feb 20207:00 amRNSMarketing update
17th Feb 20207:06 amRNSDistributor agreement for LPLDL®
12th Feb 20207:00 amRNSExtension of LPLDL® into Dairy Products
31st Jan 20207:00 amRNSLaunch of SlimBiome® in North America
28th Jan 20207:00 amRNSExtension of term and territories for products
27th Jan 20207:00 amRNSLaunch of LPLDL® product with AlfaSigma
17th Jan 20207:00 amRNSTrading Update
8th Jan 20207:00 amRNSLPLDL® reduces high blood pressure
7th Jan 20207:00 amRNSLaunch of SlimBiome® range in Holland & Barrett
19th Dec 20197:00 amRNSSlimBiome® distribution agreement for Germany
17th Dec 20197:00 amRNSAnthem BioPharma launches two products in India
9th Dec 20197:00 amRNSDistribution agreement for CholBiome®x3
6th Dec 20197:00 amRNSGoFigure® and SlimBiome® commercial updates
5th Dec 20197:00 amRNSSlimBiome® Medical update
4th Dec 20197:00 amRNSAppointment of European Sales Leader - ProBiotix
6th Nov 201910:38 amRNSHolding(s) in Company
9th Oct 20197:00 amRNSLPLDL® Pharmaceutical GMP process validation
18th Sep 20197:00 amRNSGoFigure® agreement for Southern Africa
28th Aug 201910:00 amRNSDirector's Dealing
28th Aug 20197:00 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSDirectorate Change
28th Aug 20197:00 amRNSHalf-year Report
12th Aug 20197:00 amRNSManufacturing, supply and profit sharing agreement
29th Jul 20194:03 pmRNSTransfer of certain SkinBioTherapeutics plc shares
18th Jul 20197:00 amRNSOnline distribution agreement - SlimBiome® Medical
11th Jul 20197:00 amRNSScientific and commercial update
3rd Jul 20197:00 amRNSLicense agreement for LPLDL® in Japan
1st Jul 20197:00 amRNSLPLDL® license agreement with Kappa Bioscience AS
25th Jun 20197:00 amRNSAppointment of goetzpartners securities Limited
24th Jun 20197:00 amRNSManufacturing agreement with Agropur
11th Jun 20194:55 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.